Activation of cAMP signaling attenuates impaired hepatic glucose disposal in aged male p21-activated protein kinase-1 knockout mice

Endocrinology

Volumn 155, Issue 6, 2014, Pages 2122-2132

  Chiang, Yu Ting Alex ^a,b   Ip, Wilfred ^a,b   Shao, Weijuan ^a   Song, Zhuolun Eric ^a   Chernoff, Jonathan ^c   Jin, Tianru ^a,b  

^a UNIVERSITY HEALTH NETWORK   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c FOX CHASE CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,2' DIHYDROXY 1,1' BINAPHTHYLDISULFIDE; CYCLIC AMP; ENZYME INHIBITOR; FORSKOLIN; GLUCAGON LIKE PEPTIDE 1; GLUCOSE; MESSENGER RNA; P21 ACTIVATED KINASE 1; PROGLUCAGON; PYRUVIC ACID; SITAGLIPTIN; UNCLASSIFIED DRUG; P21 ACTIVATED KINASE; PYRAZINE DERIVATIVE; TRIAZOLE DERIVATIVE;

AGED; ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CELL ISOLATION; CONTROLLED STUDY; ENZYME ACTIVITY; GENE EXPRESSION; GLUCONEOGENESIS; GLUCOSE TRANSPORT; INSULIN TOLERANCE TEST; LIVER CELL; MALE; MOUSE; NONHUMAN; ORAL GLUCOSE TOLERANCE TEST; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; SIGNAL TRANSDUCTION; ANIMAL; BLOOD; CELL CULTURE; DEFICIENCY; GENETICS; KNOCKOUT MOUSE; LIVER; METABOLISM; REAL TIME POLYMERASE CHAIN REACTION;

ANIMALS; CELLS, CULTURED; COLFORSIN; CYCLIC AMP; GLUCAGON-LIKE PEPTIDE 1; GLUCOSE; HEPATOCYTES; LIVER; MALE; MICE; MICE, KNOCKOUT; P21-ACTIVATED KINASES; PYRAZINES; REAL-TIME POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; TRIAZOLES;

EID: 84901453185     PISSN: 00137227     EISSN: 19457170     Source Type: Journal    
DOI: 10.1210/en.2013-1743     Document Type: Article

References (52)

1. Bokoch GM. Biology of the p21-activated kinases. Annu Rev Biochem. 2003;72: 743-781.
2. Arias-Romero LE, Chernoff J. A tale of two Paks. Biol Cell. 2008; 100: 97-108.
3. SellsMA, Knaus UG, Bagrodia S, AmbroseDM, BokochGM, Chernoff J. Human p21-activated kinase (Pak1) regulates actin organization in mammalian cells. Curr Biol. 1997;7: 202-210.
4. Kowluru A. Small G proteins in islet β-cell function. Endocr Rev. 2010;31: 52-78.
5. Guo D, Tan YC, Wang D, et al. A Rac-cGMP signaling pathway. Cell. 2007;128: 341-355.
6. Tsakiridis T, Taha C, Grinstein S, Klip A. Insulin activates a p21-activated kinase in muscle cells via phosphatidylinositol 3-kinase. J Biol Chem. 1996;271: 19664-19667.
7. Chiu TT, Jensen TE, Sylow L, Richter EA, Klip A. Rac1 signalling towards GLUT4/glucose uptake in skeletal muscle. Cell Signal. 2011;23: 1546-1554.
8. WangZ, OhE, Thurmond DC. Glucose-stimulated Cdc42 signaling is essential for the second phase of insulin secretion. J Biol Chem. 2007;282: 9536-9546.
9. Lim GE, Huang GJ, Flora N, LeRoith D, Rhodes CJ, Brubaker PL. Insulin regulates glucagon-like peptide-1 secretion from the enteroendocrine L cell. Endocrinology. 2009;150: 580-591.
10. Wang Z, Oh E, Clapp DW, Chernoff J, Thurmond DC. Inhibition or ablation of p21-activated kinase (PAK1) disrupts glucose homeostatic mechanisms in vivo. J Biol Chem. 2011;286: 41359-41367.
11. Aaboe K, Knop FK, Vilsbøll T, et al. Twelve weeks treatment with the DPP-4 inhibitor, sitagliptin, prevents degradation of peptide YY and improves glucose and non-glucose induced insulin secretion in patients with type 2 diabetes mellitus. Diabetes Obes Metab. 2010; 12: 323-333.
12. Chiang YT, Jin T. P21-activated protein kinases and their emerging roles in glucose homeostasis.Am J Physiol Endocrinol Metab. 2014; 306: E707-E722.
13. Sun J, Khalid S, Rozakis-AdcockM, Fantus IG, Jin T. P-21-activated protein kinase-1 functions as a linker between insulin and Wnt signaling pathways in the intestine. Oncogene. 2009;28: 3132-3144.
14. Chiang YA, Shao W, Xu XX, Chernoff J, Jin T. P21-activated protein kinase 1 (Pak1) mediates the cross talk between insulin and β-catenin on proglucagon gene expression and its ablation affects glucose homeostasis in male C57BL/6 mice. Endocrinology. 2013; 154: 77-88.
15. Cheng KK, Iglesias MA, Lam KS, et al. APPL1 potentiates insulinmediated inhibition of hepatic glucose production and alleviates diabetes via Akt activation in mice. Cell Metab. 2009;9: 417-427.
16. Vu V, Liu Y, Sen S, Xu A, Sweeney G. Delivery of adiponectin gene to skeletal muscle using ultrasound targeted microbubbles improves insulin sensitivity and whole body glucose homeostasis. Am J Physiol Endocrinol Metab. 2013;304: E168-E175.
17. Chen Z, Sheng L, Shen H, et al. Hepatic TRAF2 regulates glucose metabolism through enhancing glucagon responses. Diabetes. 2012;61: 566-573.
18. Sheng L, Zhou Y, Chen Z, et al. NF-βB-inducing kinase (NIK) promotes hyperglycemia and glucose intolerance in obesity by augmenting glucagon action. Nat Med. 2012;18: 943-949.
19. Hvidberg A, Nielsen MT, Hilsted J, Orskov C, Holst JJ. Effect of glucagon-like peptide-1 (proglucagon 78-107amide) on hepatic glucose production in healthy man. Metabolism. 1994;43: 104-108.
20. Seghieri M, Rebelos E, Gastaldelli A, et al. Direct effect of GLP-1 infusion on endogenous glucose production in humans. Diabetologia. 2013;56: 156-161.
21. Deacon SW, Beeser A, Fukui JA, et al. An isoform-selective, smallmolecule inhibitor targets the autoregulatory mechanism of p21-activated kinase. Chem Biol. 2008;15: 322-331.
22. Hoover WC, Zhang W, Xue Z, et al. Inhibition of p21 activated kinase (PAK) reduces airway responsiveness in vivo and in vitro in murine and human airways. PLoS One. 2012;7: e42601.
23. Allen JD, Jaffer ZM, Park SJ, et al. p21-activated kinase regulates mast cell degranulation via effects on calcium mobilization and cytoskeletal dynamics. Blood. 2009;113: 2695-2705.
24. Yu Z, Shao W, Chiang Y, et al. Oltipraz upregulates the nuclear factor (erythroid-derived 2)-like 2 [corrected](NRF2) antioxidant system and prevents insulin resistance and obesity induced by a high-fat diet in C57BL/6J mice. Diabetologia. 2011;54: 922-934.
25. Shao W, Wang D, Chiang YT, et al. The Wnt signaling pathway effector TCF7L2 controls gut and brain proglucagon gene expression and glucose homeostasis. Diabetes. 2013;62: 789-800.
26. Shao W, Yu Z, Chiang Y, et al. Curcumin prevents high fat diet induced insulin resistance and obesity via attenuating lipogenesis in liver and inflammatory pathway in adipocytes. PLoS One. 2012;7: e28784.
27. Zhande R, Zhang W, Zheng Y, et al. Dephosphorylation by default, a potential mechanism for regulation of insulin receptor substrate-1/2, Akt, and ERK1/2. J Biol Chem. 2006;281: 39071-39080.
28. Prigeon RL, Quddusi S, Paty B, D'Alessio DA. Suppression of glucose production by GLP-1 independent of islet hormones: a novel extrapancreatic effect. Am J Physiol Endocrinol Metab. 2003;285: E701-E707.
29. Drucker DJ, Jin T, Asa SL, Young TA, Brubaker PL. Activation of proglucagon gene transcription by protein kinase-A in a novel mouse enteroendocrine cell line. Mol Endocrinol. 1994;8: 1646-1655.
30. Jin T. The WNT signalling pathway and diabetes mellitus. Diabetologia. 2008;51: 1771-1780.
31. Lü F, Jin T, Drucker DJ. Proglucagon gene expression is induced by gastrin-releasing peptide in a mouse enteroendocrine cell line. Endocrinology. 1996;137: 3710-3716.
32. Yi F, Brubaker PL, Jin T. TCF-4 mediates cell type-specific regulation of proglucagon gene expression by β-catenin and glycogen synthase kinase-3β. J Biol Chem. 2005;280: 1457-1464.
33. Yi F, Sun J, Lim GE, et al. Cross talk between the insulin and Wnt signaling pathways: evidence from intestinal endocrine L cells. Endocrinology. 2008;149: 2341-2351.
34. Ni Z, Anini Y, Fang X, Mills G, Brubaker PL, Jin T. Transcriptional activation of the proglucagon gene by lithium and β-catenin in intestinal endocrine L cells. J Biol Chem. 2003;278: 1380-1387.
35. He H, Shulkes A, Baldwin GS. PAK1 interacts with β-catenin and is required for the regulation of the β-catenin signalling pathway by gastrins. Biochim Biophys Acta. 2008;1783: 1943-1954.
36. He H, Huynh N, Liu KH, et al. P-21 activated kinase 1 knockdown inhibits β-catenin signalling and blocks colorectal cancer growth. Cancer Lett. 2012;317: 65-71.
37. Zhu G, Wang Y, Huang B, et al. A Rac1/PAK1 cascade controls β-catenin activation in colon cancer cells. Oncogene. 2012;31: 1001-1012.
38. Arias-Romero LE, Villamar-Cruz O, Huang M, Hoeflich KP, Cherdoi: noff J. PAK1 kinase links ErbB2 to β-catenin in transformation of breast epithelial cells. Cancer Res. 2013;73: 3671-3682.
39. Deacon CF, Wamberg S, Bie P, Hughes TE, Holst JJ. Preservation of active incretin hormones by inhibition of dipeptidyl peptidase IV suppresses meal-induced incretin secretion in dogs. J Endocrinol. 2002;172: 355-362.
40. Vella A. Mechanism of action of DPP-4 inhibitors-new insights. J Clin Endocrinol Metab. 2012;97: 2626-2628.
41. Bock G, Dalla Man C, Micheletto F, et al. The effect of DPP-4 inhibition with sitagliptin on incretin secretion and on fasting and postprandial glucose turnover in subjects with impaired fasting glucose. Clin Endocrinol (Oxf). 2010;73: 189-196.
42. Baggio LL, Drucker DJ. Biology of incretins: GLP-1 and GIP. Gastroenterology. 2007;132: 2131-2157.
43. Turton MD, O'Shea D, Gunn I, et al. A role for glucagon-like peptide-1 in the central regulation of feeding. Nature. 1996;379: 69-72.
44. Meier JJ, Gallwitz B, Salmen S, et al. Normalization of glucose concentrations and deceleration of gastric emptying after solid meals during intravenous glucagon-like peptide 1 in patients with type 2 diabetes. J Clin Endocrinol Metab. 2003;88: 2719-2725.
45. Ban K, Noyan-Ashraf MH, Hoefer J, Bolz SS, Drucker DJ, Husain M. Cardioprotective and vasodilatory actions of glucagon-like peptide 1 receptor are mediated through both glucagon-like peptide 1 receptor-dependent and -independent pathways. Circulation. 2008; 117: 2340-2350.
46. Knauf C, Cani PD, Perrin C, et al. Brain glucagon-like peptide-1 increases insulin secretion and muscle insulin resistance to favor hepatic glycogen storage. J Clin Invest. 2005;115: 3554-3563.
47. Toft-Nielson M, Madsbad S, Holst JJ. The effect of glucagon-like peptide I (GLP-I) on glucose elimination in healthy subjects depends on the pancreatic glucoregulatory hormones. Diabetes. 1996;45: 552-556.
48. Larsson H, Holst JJ, Ahrén B. Glucagon-like peptide-1 reduces hepatic glucose production indirectly through insulin and glucagon in humans. Acta Physiol Scand. 1997;160: 413-422.
49. Orskov C, Wettergren A, Holst JJ. Biological effects and metabolic rates of glucagonlike peptide-1 7-36 amide and glucagonlike peptide-1 7-37 in healthy subjects are indistinguishable. Diabetes. 1993;42: 658-661.
50. Shirakawa J, Fujii H, Ohnuma K, et al. Diet-induced adipose tissue inflammation and liver steatosis are prevented by DPP-4 inhibition in diabetic mice. Diabetes. 2011;60: 1246-1257.
51. Sylow L, Jensen TE, Kleinert M, et al. Rac1 signaling is required for insulin-stimulated glucose uptake and is dysregulated in insulinresistant murine and human skeletal muscle. Diabetes. 2013;62: 1865-1875.
52. Liu H, Fergusson MM, Wu JJ, et al. Wnt signaling regulates hepatic metabolism. Sci Signal. 2011;4: ra6.